Table 3

Crude and adjusted HRs for the association between the use of glyburide and the risk of site-specific cancers

ExposureEventsPerson-yearsIncidence rate (95% CI)aCrude HRAdjusted HR (95% CI)b
Prostate cancer
 Other second-generation sulfonylureas586181,4553.2 (3.0–3.5)1.001.00 (reference)
 Glyburide7020,0263.5 (2.7–4.4)1.011.11 (0.84–1.47)
Breast cancer
 Other second-generation sulfonylureas21168,7643.1 (2.7–3.5)1.001.00 (reference)
 Glyburide3510,0433.5 (2.4–4.8)1.121.19 (0.78–1.79)
Lung cancer
 Other second-generation sulfonylureas472250,2191.9 (1.7–2.1)1.001.00 (reference)
 Glyburide5130,0691.7 (1.3–2.2)0.870.93 (0.88–0.99)
Colorectal cancer
 Other second-generation sulfonylureas456250,2191.8 (1.7–2.0)1.001.00 (reference)
 Glyburide5930,0692.0 (1.5–2.5)1.041.11 (0.82–1.51)
  • aPer 1,000 person-years.

  • bAdjusted for variables listed in Table 1 and for the use of antidiabetic drugs (metformin, thiazolidinediones, incretin-based drugs, insulin, and other oral hypoglycemic drugs) during follow-up as non–mutually exclusive time-dependent variables. For prostate cancer, the model is additionally adjusted for prostate-specific antigen screening; for breast cancer, ever use of oral contraceptives and hormone replacement therapy, and previous mammography screening; for lung cancer, history of tobacco-related conditions (chronic obstructive pulmonary disease, ischemic heart disease, and vascular diseases), history of lung diseases (pneumonia, tuberculosis, and history of chronic lung disease), and factors associated with sex hormone disorders (hypothalamic, pituitary, testis, ovarian, and adrenal gland); and for colorectal cancer, cholecystectomy, inflammatory bowel disease (Crohn’s disease and ulcerative colitis), and history of polyps.